Of note, PDL2 was independently associated with clinical response in anti-PD1-treated head and neck cancer patients, indicating that presence or absence of PDL2 expression may play a role in the response to ICI-based immunotherapy [35]. This evidence concerns the gene PDCD1LG2 and head and neck cancer.